Diabetic retinopathy is a growing problem for patients and healthcare providers — it is the leading cause of vision loss and blindness among adults between 20 and 74 years of age. Up to 80% of individuals with diabetes may develop some stage of diabetic retinopathy.1 With early diagnosis and treatment, vision loss from diabetic retinopathy is 95% preventable.
To help healthcare organizations enhance services to patients living with diabetes, the Welch Allyn RetinaVue care delivery model offers an easy-to-use solution for delivering diabetic retinal exams anywhere the patient is. While made for primary care settings, our solution includes all hardware, software and medical services needed to perform diabetic retinal exams effectively and economically at the point of care: mobile clinics, retail clinics, nursing homes and primary care offices.
Check out the eBook below to learn more about increasing access to diabetic retinal exams with a simple, affordable and flexible solution.
What's inside the eBook:
- Expanding primary care services with diabetic retinal exams
- Learn how teleretinal programs such as the RetinaVue care delivery model can help providers increase access to diabetic retinopathy exams
Download the eBook by completing the form.
- Diabetic Retinopathy Preferred Practice Pattern® from the American Academy of Ophthalmology, http://dx.doi.org/10.1016/j.ophtha.2019.09.025, ISSN 0161-6420/19.
Baxter, RetinaVue and Welch Allyn are trademarks of Baxter International Inc. or its subsidiaries.
Azure and Microsoft are trademarks of Microsoft Corporation.
HEDIS is a trademark of the National Committee for Quality Assurance (NCQA).
US-FLC147-240149 (v1.0) 11/2024